Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia
Shots:
- Arcutis will receive $30M up front, ~$64.25M upon achievement in regulatory & sales milestones along with royalties & lead the development & commercialization of Zoryve in the US & other geographies
- Huadong to get an exclusive license for cream & foam formulations of roflumilast (PDE4) inhibitor for multiple dermatological conditions incl. PsO, seborrheic dermatitis, AD & additional dermatological conditions in the future
- Huadong will lead the development, manufacturing & commercialization of roflumilast (0.3%) and other topical roflumilast in Greater China and Southeast Asia with the oversight of a joint steering committee comprised of individuals from both companies. Roflumilast was approved in the US for PsO in adults & adolescents
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
